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At the 12th Annual HUPOWorld Congress of Proteomics in Japan, the Human Pro-
teome Project (HPP) presented 16 scientific workshop sessions. Here we summarize
highlights of ten workshops from the Biology and Disease-driven HPP (B/D-HPP)
teams and three from theHPPResource Pillars.Highlights of the threeChromosome-
centric HPP sessions appeared in the many articles of the 2014 C-HPP special issue
of the Journal of Proteome Research [1].
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1 Introduction
The HUPO Human Proteome Project (HPP) is a very active global program, with
nearly 50 teams engaged in experimental research, extensive data mining, and
resource development [2–4]. The goals of the HPP are (i) major progress in mak-
ing proteomics technologies and knowledge practical and accessible for wide use
across the life sciences and biomedical research communities and (ii) completing
a gene-centric parts list for proteins and their isoforms. The Grand Challenge is
to use proteomics to bridge major gaps between evidence of genomic variation
and diverse phenotypes [5]. Much of that progress lies in understanding and visu-
alizing the biochemical and signaling pathways that capture environmental and
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behavioral interactionswith genetic predispositions, in identifying and quantifying
the protein complexes that serve as functional modules to catalyze most biological
functions, in determining the roles of protein isoforms and their protein–protein
interactions and on identifying the roles of noncoding RNAs and other regulatory
features identified with ENCODE, the Encyclopedia of DNA Elements.
Here we present highlights of the biology and disease-driven component of
the HPP and the knowledge base, antibody capture, and MS resource pillars, as
reflected in the well-attended and quite lively scientific workshops at the 12th
Annual HUPO Congress, in Yokohama, Japan, September 14–18, 2013.
2 Workshop summaries
2.1 Knowledge base resource pillar (KBpC) and proteomics standards
initiative (PSI)
(Chaired by Lydie Lane, SIB, Geneva, Switzerland, and Henning Hermjakob, EBI,
UK.)
For the Proteomics Standards Initiative, Eric Deutsch (Institute for Systems Bi-
ology, Seattle, USA) reported that, during the past year, the mzQuantML standard
for quantitative information and the correspondingMIAPEQuant guidelines were
finalized and published. mzML (MS data), mzIdentML (peptide/protein identifi-
cations), TraML (SRM transition lists), and PSI-MI (molecular interactions) are
all stable standards. Under development are mzTab (tabular format for identifi-
cation and quantification results) and PEFF (extended FASTA format for protein
sequence databases).
Henning Hermjakob reported that the ProteomeXchange (PX) submission
pipeline has been in production since summer 2012, involving at present PRIDE
(for MS/MS data) and PeptideAtlas/PASSEL (for SRM data). ProteomeXchange is
working closely together with the PSI, with many overlapping staff. Other reposi-
tories could join in the near future. The idea is to have a mutual backup to ensure
long-term sustainability. The system is heavily used, with more than 400 datasets
submitted in the first year [and >650 at the end of 2013]; many uploaded datasets
are not publicly released until the relevant manuscript is accepted. Their avail-
ability during peer review is valuable to authors and reviewers alike. The HPP
requires that investigators submit their experimental datasets to PX and cite the
PXD identifier at the end of the Abstract and in the Methods. Datasets can be
centrally searched at ProteomeCentral (proteomecentral.proteomexchange.org).
Integration of ProteomicsData in neXtProtwas described by Lydie Lane. Protein
and peptide/PTM identifications from PeptideAtlas and 20 additional curated
large-scale proteomics datasets have been integrated in neXtProt. All peptides
from PeptideAtlas human builds were integrated as ‘‘gold’’ (protein evidence level
1). In total, 420 330 peptides were mapped to 15 509 proteins and 45 430 PTM
annotations were integrated. Information is integrated with RNA expression data
from different sources and protein expression data from theHuman Protein Atlas.
There are five levels of ‘‘Protein Existence” (PE) in neXtProt: level 1 (evidence at
the protein level) is given for 15 509 proteins (out of 20 128 entries in SwissProt);
among them 1,216 proteins that have PE level 1 were validated by methods other
than MS. At the transcriptome level (PE level 2) 17.7% of the remaining proteins
have evidence of expression. [6] (See Lane et al., J Proteome Res 2014, for detailed
assessment of evidence and for metrics of the Human Proteome Project.)
In discussion, participants emphasized that the amount of proteomics data
submitted to public resources keeps increasing.HPP datasets have to be submitted
to ProteomeXchange. Reviewers should reinforce this requirement. Thewiki of the
C-HPP is a useful resource, but information needs to be extended and improved.
A workshop during the HUPO conference aimed to improve the wiki and its use.
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2.2 Antibody pillar committee and human antibody initiative
(Chaired by Matthias Uhlen, Sweden, and Michael Snyder, USA.)
The chairs highlighted the contribution of antibodies to the human proteome
project, the challenge of demonstrating antibody performance and specificity in
different kinds of assays, the huge and increasing number of antibodies, multiple
protein capture technologies, and the marriage of antibody and MS approaches.
Ed Nice (Monash University, Australia) described the Victoria antibody initia-
tive, a one-stop shop for antibodies. They have producedwith robotic infrastructure
>1000 hybridoma cell lines from 500 to 1000 projects per year of monoclonal Ab
production in twomice per antigen. Validation is performed on SDS-PAGE,West-
ern blot, surface plasmon resonance, cell sorting, and immunohistochemistry.
Phage display is utilized in parallel. They are engaged in chromosome 7 and chro-
mosome 17 projects, with a pilot project using 94 PrESTs, including olfactory
receptors as targets. They collaborate with SciLifeLab and the Human Protein
Atlas in Stockholm. Their antibodies are available on favorable terms for HPP
investigators.
Peter Nilsson (Sweden) presented the EuropeanUnion Affinomics consortium,
led byMichael Taussig. Established in 2010, this AffinityProteome binders project
comprises 19 partners and seven working parties, from generation of binders,
antigens, and databases, to molecular tools and validation by immunohistochem-
istry, immunofluorescence, Western blot, and protein microarrays. Antigen pro-
duction for the targets specified by the program has been completed; binder
production is 75% complete. For example, KTH has delivered 60 PrEST anti-
gens and 800 binders. They have focused on renewable binders of different scaf-
folds for 1000 targets on kinases, SH2, phosphatases, and cancer related proteins
(www.proteinbinders.org).
From the United States, Salvatore Sechi of NIH (Bethesda, MD) reviewed the
parameters of the program of renewable antibody reagents. The pilot at seven
centers is focused on transcription factors; two centers dealing with antigens are
using recombinant antibody network immunoprecipitation and protein arrays
with monospecific monoclonal antibodies; the other centers are improving the
pipeline from target selection to reagent distribution with diverse platforms. There
is a central website to access these binders. The centers interact with Human
Protein Atlas and Affinomics.
A major annotated database for antibodies, mostly commercial, is Antibodype-
dia. Tove Alm (Sweden) described the combined efforts of academia and com-
panies. Interested researchers can track information about available antibodies
for various applications, with some annotation from the shared experience of the
broader community. Features include a gene-centric structure, search and com-
pare functions, advanced filtering options (e.g. application), and direct link to
provider. Nearly 1 000 000 nonunique antibodies are entered in the portal, cover-
ing 90% of human genome, with information organized by chromosome. About
72% of all genes (15 000) have>10 antibody entries, 19% (3900) have 1–9, and 9%
(1900) have no antibody. For example, there are 2500 antibodies listed for EGFR.
In all there are >100 000 publication references, providing useful information
about antibody functionality.
There was extensive discussion. ShouldHUPO offer a service of quality-assured
antibodies? No, the data should speak for themselves, reflecting data labs, different
applications, but different results for the same listed antibody. General endorse-
ments are not appropriate. Antibodypedia welcomes conflicting reports; however,
there have actually been relatively few contributions. Users extract information far
more than contributing information. UniProt similarly has had low participation
from the community for its Wikipedia approach. Experience shared via UCSC
Genome Browser indicates that about 50% of polyclonal antibodies and 30% of
monoclonal antibodies “work,” a very rough summary of extremely heterogeneous
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applications. Off-target binding remains common to all binding reagents. The
overall focus remains on relatively few targets with many binders. Overall 70% of
Ab binders are polyclonal and 30%monoclonal. There are multiple other binders,
including SOMAmers with pM affinity reported. Methods for high throughput
production of recombinant binders require further development. Clones of mAb
remain available, for example, in the hybridoma bank at the University of Iowa.
2.3 The human EyeOME (HEPP)
(Organized by Richard Semba, Johns Hopkins, USA, the newest B/D-HPP initia-
tive participating was the HEPP.)
Jennifer van Eyk (Johns Hopkins) noted that investigative proteomic tools can
transform vision science and enhance understanding of physiology and disease
processes that affect sight. An estimated 285million people worldwide have major
visual impairment; 39 million are blind. A literature review of 4842 total pro-
teins reported for eight different eye compartments was published by the HEPP
[7, 8]. HEPP goals are to standardize tissue collection methods, establish a repos-
itory, develop a reference data set, exchange trainees, and develop an Eyeome
community.
The human tear proteomewas introduced by Zhou Lei (Singapore Eye Research
Institute andDuke-NationalUniversity of Singapore). Tears are an easily accessible
body fluid covering the ocular surface; 1500 proteins have been identified from
normal human tears. One dimensional-RPLC-MS/MS identified 500–700 tear
proteins using 4 mg of total tear proteins (0.5 mL tears), and MS/MS ALL with
SWATH acquisition enabled MRM-based quantitation of 500 proteins.
Roger Beuerman (Singapore) discussed biomarker development using tears
for several inflammatory disorders. Clinical severity of the dry eye condition was
correlated with a four-protein biomarker panel. Similar biomarkers for MGD,
pterygium, thyroid eye disease, and lacrimal gland tumors correlated with disease,
and may outperform current clinical signs and testing. Tear biomarkers even
distinguished between surgical wounds created by different instruments. An on-
going clinical trial using tear proteomic biomarkersmay outperform lengthy, often
inconclusive clinical observations. The audience discussed specific methods for
optimizing tear protein collection, how quantitative biomarker measurements can
correlate with disease severity, and international tissue sharing and collaboration.
The anterior segment proteome is important for glaucoma studies, as described
by Deepak Edward (Johns Hopkins and King Khalid Eye Hospital, Saudi Arabia).
Glaucoma is a heterogeneous group of diseases leading to optic neuropathy, a
leading cause of blindness globally. Glaucoma involves impairment of the aqueous
humor (AH) outflow from the anterior chamber. Proteomic analyses of the AH,
ciliary body, iris, and trabecular meshwork are relevant to disease pathogenesis.
The normal iris proteome included 550 proteins. The AH proteome of controls
and primary congenital glaucoma (PCG) patients and biomarkers associated with
other types of glaucoma are under study in the AH, ciliary body, and trabecular
meshwork.
Vinit Mahajan (University of Iowa, USA) presented proteomic studies of pa-
tients with genetically identical inflammatory vitreoretinal disease. Disease stage-
specific cytokines were identified in surgical samples from patients with inherited
CAPN5-associated vitreoretinal disease. Proteomic profiles differentiated drug-
responsive and nonresponsive pathways. The absence of TNF-alpha and B-cell
markers correlated with prior treatment failure using infliximab and B-cell im-
munosuppression. Biomarkers showed anti-VEGF therapy was highly effective in
controlling neovascularization aswas anti-IL-17 therapy for vitreous inflammation.
Failure to control pathologic fibrosis was associated with persistent expression of
IL-6; IL-6 therapy improved a case of tractional retinal detachment. The audience
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discussed the limits of genomics for personalized medicine and the advantages of
proteomics to identify disease stages and severity.
2.4 Cancer human proteome project
(Chairs, Hui Zhang, Johns Hopkins, USA; Christopher Kinsinger, NCI, USA;
Juan Pablo Albar, Spain.)
As stated by Hui Zhang, the goals of the cancer human proteome project (Ca-
HPP) are (1) to identify and prioritize proteins related to specific cancer pathways
and cancer types, and (2) to generate and disseminate assays and resources to sup-
port the analysis of biological networks underlying biological processes or clinical
investigations of cancer, including antibodies, affinity-based arrays, targeted MS,
and immuno-MRM.
Christopher Kinsinger described the Proteogenomics Network of the Cancer
Clinical Proteomic Tumor Analysis Consortium (CPTAC), National Cancer In-
stitute, USA. The CPTAC is currently analyzing approximately 100 tumors from
each of three tumor types: colorectal, breast, and ovarian cancers. Both proteomic
and genomic data and antibodies are publicly available. In addition, the network
is developing a portal for MRM and immuno-MRM assays.
Analysis of tissue biopsies by pressure cycling technology (PCT) SWATH was
the theme of Guo Tiannan (ETH Zurich, Institute of Molecular Systems Biology,
Switzerland). A PCT to lyse tissue frombiopsies for proteomic analysis by SWATH
reproducibly yields 50g of peptides from 1mgwet weight tissue in a process that
lasts 12 h, across a variety of samples. Applied to 18 kidney tumor biopsies, the CV
was 20% for the raw SWATH signals, 10% for MS2 spectra, and 20% for the MS1
spectra. SWATH identified some 3000 proteins in common across the samples,
while data-dependent analysis (DDA) detected many more proteins in only one
sample but fewer proteins consistently across the cohort. Using the OPEN-Swath
software tool to cluster the PCT-SWATH data, known subtypes of kidney cancer
(papillary and clear cell) were clearly distinguished.
Peter James (Lund University, Sweden) presented research on DNA repair
pathways in breast cancer. An elaborate workflow was applied to 15 000 fresh
frozen breast cancer tissue samples and breast cancer cell lines to identify and
classify proteins by organelle, select proteins associated with DNA damage repair,
and develop SRM assays for those proteins. The heterogeneity of tumor tissue
is clearly revealed when cells are FACS sorted prior to analysis. Another issue is
different proteomes between cell model and human tumor. Of 13 241 proteins
identified across the sample cohort, 3000 were unique to tumor, 3000 unique
to cell line, and 7400 in common; 250 proteins are involved with DNA damage
repair. For breast cancer subtypes treated with various chemotherapeutic agents,
the assay confirms chemosensitivity in Luminal A samples and chemoresistance
in Basal tumors.
Integrative Analysis: Bridging the Gaps in Genetic Information Flow between
Genomic and Proteomic Data was the topic of Zhen Zhang (Johns Hopkins,
USA). Challenges of cancer proteomics include intratumor heterogeneity, dearth
of shared genomic aberrations within the same histopathological tumor subtype,
many data gaps, lack of early-stage disease-specific signals, low prevalence, limited
statistical power, and overfitting of data. The solution space at a given false discov-
ery rate is too large for cost-effective follow-up studies. One solution is to reduce the
solution space by triangulatingmultiple data sets of different types and/or sources.
For example, proteomic and genomic data for CompRef, a xenograft-based sam-
ple used by CPTAC, served as a training set for differential analysis, enrichment
analysis, network signature identification, and then validation by network-based
classification. The result separated basal and luminal subtypes from a test set of
samples.
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Edouard Nice (Monash University, Australia) spoke about proteomics-based
biomarker studies of colorectal cancer. Their three-stage approach to identify can-
didate biomarkers comprises (1) an inventory of proteins in 10 colon cancer-
associated human cell lines, with 1D-SDS nanoLC-MS/MS of secretome and exo-
some of each cell line; (2) search for the 2500 proteins so identified in fecalmaterial
from the APCmin mouse model of colon cancer, using 1D and multidimensional
purification steps, yielding 91 murine proteins of interest; and (3) collection and
planned SRM analysis of fecal samples from ten human colon cancer subjects and
five normal subjects.
Dong Li (Beijing Proteome Research Center, China) described proteome-wide
prediction of the substrate for human ubiquitin-protein ligase. Several methods
are being employed to predict and identify substrates for the E3 component of the
ubiquitin-proteasome system.
Panel discussion was led by Hisashi Narimatsu, Tadashi Kondo, and Ignacio
Casal. Each panel member raised the issue of intratumor heterogeneity. Laser-
capture microdissection was recommended. Another suggestion was to consider
2D-PAGE rather than MS as the primary analysis method. The panel was highly
supportive of the use of animalmodels to understand cancer proteomes, but clearly
recognized the importance of answering the requirements of clinicians, not just
scientific curiosity.
Ruedi Aebersold encouraged the group to pool resources as a means to enable
access to results and reagents to as many researchers as possible. One way to do
this for SRM assays would be to set up a cancer-specific section of SRMAtlas.
Another solution would be to expand the CPTAC portals for antibodies and SRM
assays to allow deposition of reagents and assays from outside of CPTAC. The
CPTAC guidelines would be maintained for all depositors. Kinsinger asked how
to define a Ca-HPP; for instance, how many tumors of a given cancer type would
constitute a sufficient set of characterized samples? Moreover, the source of the
samples poses no small challenge, particularly if proteomic analysis continues to
require fresh frozen, resected tumors withminimal ischemic exposure. There was
general interest in new approaches to proteogenomic analysis, moving beyond
from protein inventory experiments toward biological insights.
Finally, discussions following the formal session revealed substantial interest in
coordination of a formal Ca-HPP. Perhaps a full-day workshop at the 2014 HUPO
World Congress is in order. Moreover, the United States has a well-coordinated
effort in this area with CPTAC, now achieving connection with the TCGA ge-
nomics/epigeomics program. It was not clear from the workshop that other re-
gions had cancer proteomics projects that extended beyond a single lab. Perhaps
this is an opportunity for the HUPO Ca-HPP.
2.5 HUPO brain proteome project (HBPP)
(Chairs Lea T. Grinberg, Sao Paulo, Brazil; Helmut E. Meyer, Bochum, Germany;
Young Mok Park, Daejeon, Korea.)
The 20th HBPP workshop of the HUPO Brain Proteome Project Initiative
(HUPO BPP) engaged 40 participants to discuss new developments in the pro-
teomics and pathology of neurodegenerative diseases. The aim of the HUPO
Brain Proteome Project Initiative is to understand human diseases which affect
the central nervous system, especially the biogenesis of Alzheimer’s disease (AD),
Parkinson’s disease (PD), and fronto-temporal dementia (FTD).
Lea T. Grinberg highlighted the Contributions of Neuropathology to Elucidat-
ing Neurodegenerative Diseases: Insights from a Revamped Science. She summa-
rized the common features of neurodegenerative diseases and reported C9orf72
mutations as the most common causes of familial FTD and FTD-ALS.
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Helmut E. Meyer presented Biomarker Discovery for Alzheimer and Parkinson
disease, and Andreas Schro¨tter (Bochum, Germany) spoke on Differential Pro-
teomic Analysis of Human Hippocampal Regions of Interest (CA1, CA2, CA3,
fascia dentata) Relevance for Autoimmunity in Alzheimer`s disease? They both
propose the hypothesis that AD arises as a result of pathology of the immune
system. The generation of autoantibodies against neuronal structures could drive
the loss of neurones leading to AD.
TheHUPObrain proteome project initiative is focused on the detailed biochem-
ical mechanism of the biogenesis of the neurological diseases and on development
of biomarkers to detect the disorders early, when changes of the biochemical equi-
librium might be compensated by specific treatment before there is irreversible
damage.
2.6 Joint human kidney/urine proteome project (HKUPP) and human
plasma proteome project (HPPP) workshop
(Chaired by Tadashi Yamamoto, Niigata, Japan, and Mark Baker, Sydney, Aus-
tralia.)
Tadashi Yamamoto presented Proteomic Analysis of Nephron Segments of
Formalin-Fixed Paraffin-Embedded Human Kidney Tissues. The HKUPP has an
on-going experimental program to show the origin of urine proteins from kidney
and from other urinary tract tissues, using MS analysis of nephron segments
and other tissue components from formalin-fixed paraffin-embedded kidney spec-
imens. The proportion of urinary proteins derived from the kidney and blood was
discussed, referring to the KHUPP database.
A Collective Analysis of Three Human Subproteomes using PeptideAtlas was
summarized by Eric Deutsch of the Institute of Systems Biology (Seattle, USA).
Comparative analysis of kidney, urine, and plasma subproteome PeptideAtlases
showed which proteins are unique to, or highly enriched in, each of the sub-
proteomes relative to the others; the same analysis revealed which urine pro-
teins were likely derived from kidney, which likely derived from plasma, and
which likely not derived from either. The detailed findings have been published
in Farrah et al., [9]. The significance of standardization for such comparisons was
discussed.
Mark Baker then led a discussion of the status and future directions for the
Human Plasma Proteome Project. He invited HUPO colleagues interested in
plasma proteomics to join an expanded mailing list and to contact him with
regard to EuPA and PanAm HUPO leadership representatives for the HPPP
going forward. Proteome analysis of the cellular components of blood cells was a
specific recommendation.
Different Levels of Variability in the human plasma proteome was discussed
by Yansheng Liu (ETH Zurich). He introduced the newly developed data inde-
pendent acquisition (DIA) method SWATH MS with quantitative analyses of the
plasma proteome. The principle of themethod and individual difference in plasma
proteome were discussed.
Bruno Domon (Luxembourg) presented Quantification of Peptides in Clini-
cal Samples based on high-resolution parallel reaction monitoring (PRM) mass
measurements. This new method for quantification of peptides extracts postac-
quisition ion traces of specific fragment ions and applies the results to the analysis
of complex clinical samples (plasma and urine). He demonstrated benefits of the
gain in selectivity and the identification of the fragments through accurate mass
to increase confidence in the measurements. The participants agreed that the
cross-initiative collaboration and the joint initiative workshop was quite useful
and stimulating.
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2.7 Human liver proteome project workshop
(Chaired by Pumin Zhang, Beijing, China; Felix Elortza, Bilbao, Spain; Fernando
Corrales, Pamplona, Spain.)
Felix Elortza described Proteomics Analyses of Urine as a Source of Liver Dis-
ease Biomarkers. Liver proteomic research continues to be a major focus for CIC
bioGUNE´s proteomics platform. For multiple liver pathologies, they employ pep-
tidome profiling and exosome proteomics with standardized protocols for urine
specimens from patients. In addition, they collaborate with Carolina Armengol
to perform differential proteomics analyses on human hepatoblastoma samples.
Hepatoblastoma is a malignant embryonal tumor of the liver usually diagnosed in
children <3 years of age. They have combined DIGE with the nLC MS/MS label-
free quantitation searching for new prognostic biomarkers. The results obtained
from both techniques are complementary.
Fernando Corrales (Pamplona, Spain) presented Identification of Proteins Driv-
ing the Progression of Liver Injury and Potential Biomarkers. They have identified
mitochondrial Prohibitin 1 as a central protein to preserve liver homeostasis;
its downregulation correlates with development of nonalcoholic steatohepatitis.
Defective prohibitin 1 induces apoptosis in human hepatoma cells; its partial dele-
tion in mice induces liver damage and an exacerbated inflammatory response.
Meanwhile, proteomic approaches led them to define a collection of proteins that
might be relevant in the progression of human hepatocellular carcinoma (HCC).
Vasodilator-stimulated phosphoprotein has emerged as a biomarker candidate for
the early detection of HCC as its plasma levels increase significantly. This change
can be detected in cirrhosis, which predisposes to HCC. A group of HCC patients
subjected to radioembolization is under study.
Toward the SystemMedicine of NonAlcoholic Fatty Liver Disease (NAFLD) was
presented by Tommy Nilsson (McGill University, Canada). NAFLD comprises a
disease spectrum from benign nonalcoholic fatty liver to nonalcoholic steatohep-
atitis (NASH) to cirrhosis and risk of hepatocellular carcinomas. Between 3 and
19% of general populations have some form of NASH (inflammation) depending
on their body mass index. The McGill liver biobank performs sample process-
ing, subcellular fractionation with organelles, and advanced bioinformatics. They
reported identification of 6053 proteins (FDR below 0.1%, per Protein Prophet/
Scaffold).
Finally, Pumin Zhang described progress made by Chinese Human Liver Pro-
teome Project collaborating groups. The summary of results is available in Liver-
base2.0 with >12 000 proteins identified from human liver; more than half were
assigned cellular locations. Liverbase3.0 will be constructed to show profiles of the
four major cell types.
2.8 Proteome biology of stem cells HUPO
(Chaired by AJR Heck, Utrecht, The Netherlands.)
Myo Kiwasaki (Kyoto University, Japan) described the use of meter scale mono-
lithic LC for in-depth analysis of induced pluripotent stem cells (iPSC) and of
fibroblasts, identifying 5000 protein groups within a single LC-MS analysis. Sub-
cellular fractionation enhanced detection of lower abundance proteins. In all,
46% of 8700 proteins were identified in both samples, while 29 and 25% were
found only in iPSC and in fibroblasts, respectively, with distinctive functional
annotations.
Albert Heck explored the Proteome Biology of Adult Stem Cells, which have
enormous potential for therapeutic applications. Because of their low abundance,
unique markers are needed for their isolation and characterization. For exam-
ple, Lgr5 was identified as one of the surface markers uniquely expressed by a
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crypt stem cell subtype (cycling CBC cells) from the intestinal epithelium. Lgr5
associates with Wnt receptor and has R-spondin as ligand. FACS sorted Lgr5+/−
cells were characterized by proteomics (4000 proteins quantitated) and transcrip-
tome analysis. Biological replicates had a Pearson correlation of 0.7 for the pro-
teomics measurement; technical replicates had r = 0.85. They found r = 0.7
between the proteomics and transcriptomics measurements.
Akhilesh Pandey (Johns Hopkins, USA) presented a study of embryoid bodies
from embryonic stem cell (ESC) differentiation and selected for neural progeni-
tor cells. Two differentiation protocols generated astrocytes and motor neurons,
respectively. Proteomics analysis using SCX prefractionation, LC-MS/MS, and
iTRAQ-8plex quantification of 1200 proteins found stage-specific dynamic mark-
ers in ES cells differentiated into neurons or astrocytes. From distinct expression
patterns, seven targets were selected for validation by WB and immunocytochem-
istry. A similar approach was useful to monitor differentiation into oligodendro-
cytes; iTRAQ 4-plex quantitated a total of 3000 proteins. Functional bioinformatics
analyses of these data are ongoing.
2.9 Human diabetes proteome project (HDPP)
(Chaired by Jean-Charles Sanchez, Geneva, Switzerland; Martin Kussman, Lau-
sanne, Switzerland; Peter Bergsten, Uppsala, Sweden.)
The theme of the HDPP is “From Network Biology to Targets for Therapies
and Prevention.” A 10-year roadmap was defined in November 2012 to focus on
beta-cells, islets, stem cells, and blood-based biomarkers with integration of all
omics platforms. Sanchez et al. launched the portal www.hdpp.info with news,
partners, the HDPP-1000 list, and information about diabetes and the broader
HPP. In all, 1379 proteins were defined as of special interest in the context of
diabetes, posted with the UniProt and neXtProt accession numbers and Peptide
Atlas and Human Protein Atlas cross-references. This draft will evolve and serve
as a starting point for sublists, such as the 25Diagnostic-HDPP and the 118 plasma
proteins and 449 islet proteins quantifiable by isobaric tagging. In all 5300 human
islet proteins were identified and integrated into the Human Islet Database and
into neXtProt. The first publication [10] appeared in Translational Proteomics, the
voice of HDPP, the inaugural article of the journal.
Domitille Schvartz (Geneva) introduced SMARTER as an alternative to SRM
for biomarker discovery of islet-specific proteins in plasma. >700 islet proteins
were quantified in plasma, of which 449 were among the HDPP-1000 proteins
of great interest for diabetes. Also, 81 proteins were quantified for the first time
in plasma (not present in the most recent Plasma Proteome Database build) and
were contributed to the HPP parts list via neXtProt.
Michael Snyder (Stanford, USA) described his Personal Omics Profiling ap-
proach, a longitudinal self-study with multiple omics platforms [11]. The aim is
prediction and early recognition of disease risks. He outlined its application to
patients with diabetes or prediabetes.
Peter Bergsten presented Beta-JUDO, the European Project on Beta-cell Func-
tion in Juvenile Diabetes and Obesity, which was integrated into the HDPP. The
goal is to generate knowledge of cell dysfunction that might inform innovative
therapies for Type 1 or Type 2 diabetes by halting destruction and/or facilitat-
ing recovery of functionally impaired metabolic tissues, particularly beta-cells.
Palmitate-induced dysfunction is an experimental model.
Martin Kussman focused on signal transduction in beta-cell mitochondria, an
essential organelle to understand insulin secretion. Phosphorylation and acetyla-
tion of mitochondrial proteins are under investigation.
YoungAhGoo (U.Maryland,USA) presentedplans to determineproteomic pro-
files of individuals at high genetic risk for development of T1 diabetes andmatched
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controls and to integrate the data with parallel transcriptomics and metabolomics
measurements. Preliminary data suggest signatures associatedwithT1Donset and
progression. Salvatore Sechi (NIDDK, NIH, USA) outlined the range of NIDDK-
funded research projects.
Finally, the rotating chairs named as deliverables for 2014 analytical results
for the HDPP-1000 proteins in plasma by MS, integration of the human and
rodent islet of Langerhans proteome databases and the human blood glycated pro-
teome database into the HDPP website, and close coordination of HDPP with the
B/D-HPP. Research projects will include mitochondrial role in beta-cell dysfunc-
tion, dysfunction of insulin-producing cell lines induced by high glucose, effects
of antiplatelet therapy on cardiovascular diseases and diabetes, and advances in
bioinformatics for network-based biology.
2.10 Cardiovascular proteome initiative
(Co-chaired by Peipei Ping, UCLA, Jenny van Eyk, Johns Hopkins, & Cathy
Costello, Boston University, USA.)
The cardiovascular workshop was focused on overcoming technical and exper-
imental challenges in the application of proteomics-based methods to the heart
and vascular system. Peipei Ping opened the session with an overview of the role
that proteomics can play in areas of cardiovascular disease. She outlined what
are the large clinical questions that our field should or could address. Anthony
Gramolini (University of Toronto, Canada) focused on his work on the difficult
but important plasma membrane proteome. His seminal work compared this
proteome across a number of heart and vascular system cell types, including pri-
mary mouse neonatal and human fetal ventricular cardiomyocytes, endothelium,
and smooth muscle cells, as well as adult human coronary artery smooth muscle
and endothelial cells, and human adult cardiac muscle-derived cardiomyocytes.
Albert Sickmann (Leibniz-Institut fu¨r Analytik, Germany) discussed how to han-
dle the really difficult and challenging cardiovascular proteomes. His laboratory
is a world-leader in the systematic characterization of human platelets in arte-
rial vascular disorders. Naoto Minamino (National Cerebral and Cardiovascular
Center Research Institute, Japan) focused on challenges in the translation from
discovery to biomarkers. He described work on dilated cardiomyopathy, seeking to
understand the underlying pathogenicmechanism and generate ideas for targeted
therapy. He also addressed the proteome analysis of disease stage classification of
aortic aneurysms. Finally, Cathy Costello and Jenny Van Eyk discussed potential
routes forward for the application of proteomics to cardiovascular disorders.
2.11 Initiative on model organism proteomes (iMOP)
(Chaired by Michael Hentgartner, Zurich, Switzerland.)
Three speakers contributed to the iMOP session, following an introduction
by Sabine Schrimpf (University of Zurich). Marc Wilkins (University of New
South Wales, Australia) addressed the methylproteome network of Saccharomyces
cerevisiae. Paola Roncada (Italian Experimental Institute, Milan, Italy) reported
on secretome protein profiling of the growth interaction between Listeria mono-
cytogenes and Lactobacillus lactis subsp. Lactis. Brian Tate Weinert (University of
Copenhagen, Denmark) spoke about how acetyl-phosphate links metabolism to
global acetylation dynamics in E. coli.
An extensive discussion followed. The group has held excellent workshops at
HUPO annual congresses for the past 4 years and is considered an integral part
of the HPP due to the importance of comparative proteomics. iMOP would like to
increase its visibility at future meetings, partly by placing iMOP presentations in
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other scientific sessions or tracks, including sessions on clinical proteomics. They
would like an option for researchers to select iMOP during the abstract submission
procedure and would like their session organizers to have better access to all the
submitted abstracts. They pointed out that the participants in the discussion repre-
sented the diverse model organism communities: bacteria, plants, animal models,
food production, and bioinformatics. Chair rotation and deliverables were also
discussed. We all congratulate Michael Hengartner on his election as president
of the University of Zurich. His successor as iMOP chair is Emoke Bendixen of
Aarhus University in Denmark.
2.12 Human glycoproteomics initiative (HGPI)
(Chaired by Hisashi Narimatsu, National Institute of Advanced Science & Tech-
nology, Japan.)
Glycoproteomicswas a dominant program theme of the Yokohama 12thAnnual
HUPO Congress, reflecting the high activity in this research area in Japan, as well
as globally. This 12th workshop of theHGPI comprised threemajor presentations,
with about 80 participants, one of the larger workshops.
Hiromi Ito (Fukushima Medical University, Japan) reported on completed and
ongoing pilot studies performed as activities of the HGPI. Two collaborative pi-
lot studies on evaluation and standardization of technologies for glycomics used
purified glycoproteins as common samples. It was concluded that the protein-
based glycomic technologies were established and can provide consistent results
across several methods. However, there are still challenges for standardization
and consistency on the glycome analysis for the purified glycoproteins. This
problem was magnified in a pilot study using complex mixtures such as cell
extracts. The major reason is inconsistency in the preanalytical stage of extraction
of glycoproteins, especially from small amounts of crude, complex samples. More
studies are planned.
The HGPI Chair, Hisashi Narimatsu, proposed evolution of the HGPI to a
new international collaboration under the HPP, the “Biology/Disease-driven Gly-
coproteome Project.” The aim is to expand the current theme of glycomics to
glycoproteomics, with technical development to merge glycomics and glycopro-
teomics; they are currently rather dissociated. The next aim is construction of a
common database to capture large-scale datasets generated with various advanced
technologies as those data emerge. The discussion recognized that this step is
quite ambitious, possibly even premature. However, all agreed that technologies
are needed to bring together peptide sequences and glycan structures. There was
enthusiasm to plan the direction of such future activity of this initiative.
Finally, Katrine ter-Borch Gram Schjoldager (Copenhaven University, Den-
mark) introduced a powerful andnovel technology to analyze theO-glycoproteome.
The technology was applied to reveal target proteins of several specific O-
glycosylation enzymes and polypeptide N-acetyl-galactosamine transferase (pp-
GalNAcT), among many isoenzymes. This technology could contribute strongly
to the proposed B/D-GPP.
2.13 Proteome analyzer MS initiative
(Chaired by Bruno Domon, Luxembourg and HUPO Industrial Advisory Board)
While genomics has progressed fromNorthern blots to microarrays to next-gen
sequencing across a great many research groups, protein studies by nonspecialists
in proteomics remain rooted in Western blots. Biologists need proteomics tools
that are readily adapted to a wide variety of laboratory applications, robust in
use, moderate in cost, and capable of high throughput analyses for clinical or
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epidemiologic studies. An analogy was presented of automobiles in the 1920s–
1930s (exclusive and cost-prohibitive, except for the wealthy) and the emergence
in the late 1930s of the Citroen 2 CV for farmers and the Volkswagen Beetle for
families.
This group is considering engineering requirements for Proteome Analyzer I,
a replacement for the Western blot, and a Proteome Analyzer II, an analogy to
RNA-Seq. Most common workflows today involve complicated chromatography
and MS strategies, which severely limit sample throughput.
Desired features for a Western blot replacement are the following: reliable
identification and quantitation of specific proteins; insight into PTMswere needed;
well-developed, highly reliable assays with integrated quality control; dynamic
range of 6–7 orders of magnitude; multiplexing capability to address 10s or 100s
of targets per experiment; easy to use and learn to use; <1 h per sample; cost in
the range of a Western blot; available in a reagent-rental model, avoiding capital
expense.
Ideal attributes of a genomics-like, RNA-Seq equivalent Proteome Analyzer II
would be comprehensive, quantitative, reproducible, fast, and sensitive. In more
detail, we seek identification and (semi)-quantitation of every protein in a cell
with, say, 50% sequence coverage, including PTMs; reproducible measurements
of differences between samples of cells; standardized workflow, including sample
preparation and data conversion; and wide accessibility for the biology commu-
nity from technical and cost perspectives, with cost points such as $1/protein or
$10 000 per cellular proteome. Biologists currently use RNA-Seq as a proxy for
protein expression and abundance, but cannot demonstrate translation of tran-
scripts to proteins, let alone critical PTMs and differential expression of splice
variant proteins.
The next steps for this initiative include a HUPO web discussion forum, a
survey targeting a wide range of biologists, close engagement with the instrument
manufacturers through the HUPO Industrial Advisory Board, and a workshop at
the next HUPO Congress, 6–8 October, 2014, in Madrid.
3 Goals of the B/D-HPP
The B/D-HPP has been created on the foundation of pre-existing HUPO ini-
tiatives on organ and biofluid proteomes (Plasma, Liver, Brain, Kidney-Urine,
Cardiovascular, Stem Cells, Model Organisms), and the Proteomics Standards
Initiative, the Human Antibody Initiative, and the Human GlycoProteomics
Initiative. New initiatives on cancers, diabetes, and the eye are now quite
active, while groups working on mitochondria, epigenetics, pediatric disor-
ders, infectious diseases, and autoimmune disorders are in early stages of
development.
The B/D-HPP aims to explore whether access to reliable and reproducible mea-
surement techniques and quality-assured resources to support these techniques
will facilitate research on a much larger fraction of the proteome by a broad range
of life scientists, beyond those representing the core proteomics community. As
described by Aebersold et al. [12], the HPP is pursuing a three-prong strategy
by providing: (i) specific, validated mass spectrometric methods to quantify the
abundance of all proteins within a focus area of biology, (ii) specific and selec-
tive protein affinity reagents for each of these proteins and their key isoforms,
and (iii) the knowledge how to use these SRM assays and reagents in a for-
mat readily accessible for the scientific community and supported by annotations
based on protein networks and pathways. In short, the B/D-HPP attempts to pro-
vide a spectrum of research tools for studying relevant proteins in specific areas
of biology and specific diseases. Biological processes and disease mechanisms
are expected to be analyzed increasingly in the full complexity of the living cell.
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Figure 1. The EyeOME, the latest addition to the B/D-HPP, addresses eight compart-
ments of the eye [7,8].
Toward this end, the B/D-HPP defined the following specific goals for its compo-
nent initiatives:
(i) Select biological focus areas. As listed above, the areas might derive from
self-organizing groups of scientists who study specific biological processes or
diseases, who recognize the essential role of proteins and their isoforms, and
who want to support the application of proteomics technologies to their field.
Optimally the specific focus areas will be discussed in workshops at future
HUPO meetings.
(ii) Generate target lists of proteins.Once the areas of biology are defined, the area
experts should deliver a list of proteins known to be, or hypothesized to be,
especially relevant for that field. For example, a biological theme on cellular
signaling might comprise all human protein kinases and phosphatases, or at
least those likely to be involved in the disease of interest. It is well understood
that these lists are subject to change and adaptation. However, even early
lists of proteins relevant for a particular disease or biological process and the
associated resources to precisely and reliably measure these proteins would
constitute significant progress toward the routine use of proteomics for the
study of the respective disease or process.
(iii) Define and generate relevant assays and reagents for these targets. The col-
laborative team of biologists, physicians, and proteomics experts should then
define the assays and reagents ofmost relevance to the problem, and generate
a scientific plan to generate and characterize those assays and reagents.
(iv) Disseminate the knowledge and reagents. The impact of the B/D-HPP will
depend on community uptake, and thus the B/D-HPP proposes that all
MS and affinity based assays and reagents would be made publicly ac-
cessible, with no restriction on use, and full datasets and useful meta-
data would be made available via ProteomeXchange and interconnected
databases.
(v) Introduce clinician-scientists to the developments in proteomics that would
be valuable for their disease-oriented research. At the Yokohama Congress,
Shiying Shao, MD, PhD, endocrinologist from Tongji Hospital, Huazhong
University of Science and Technology, Wuhan, China; Kuo-Chen Wei, MD,
chair of Neurosurgery and vice-chair Chang Gung Cancer Center, in Tai-
wan; and Leslie Chen PhD, Assistant Professor in the Medical Research
Department, Chang Gung Memorial Hospital, Taiwan, received travel fel-
lowships from HUPO to participate in the Congress and specifically with
their respective B/D-HPP groups—Diabetes, Cancers, and Brain. Due to
scheduling challenges, others who were accepted from Japan, Australia, and
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China were unable to attend. This year the announcement of the fellowships
was issued in March for the October 2014 HUPO Congress in Madrid.
The authors have declared no conflict of interest.
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